机译:凝集素增强SARS-COV-2感染和影响中和抗体
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Humabs Biomed SA Bellinzona Switzerland;
Vir Biotechnol San Francisco CA 94158 USA;
Univ Washington Dept Biochem Seattle WA 98195 USA;
Humabs Biomed SA Bellinzona Switzerland;
Univ Washington Dept Biochem Seattle WA 98195 USA;
Univ Washington Dept Biochem Seattle WA 98195 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Univ Washington Dept Biochem Seattle WA 98195 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
Humabs Biomed SA Bellinzona Switzerland;
Humabs Biomed SA Bellinzona Switzerland;
IrsiCaixa AIDS Res Inst Badalona Spain|Univ Vic Cent Univ Catalonia UVic UCC Vic Spain|Catalan Inst Res & Adv Studies ICREA Barcelona Spain;
IRTA UAB IRTA Ctr Recerca Sanitat Anim CReSA Campus UAB Bellaterra Cerdanyola Del Spain;
IrsiCaixa AIDS Res Inst Badalona Spain|Germans Trias & Pujol Res Inst IGTP Can Ruti Campus Badalona Spain;
Washington Univ Sch Med Dept Pathol & Immunol St Louis MO USA|UT Southwestern Med Ctr Dept Internal Med Dallas TX USA;
Humabs Biomed SA Bellinzona Switzerland;
Univ Washington Dept Biochem Seattle WA 98195 USA;
Vir Biotechnol St Louis MO USA;
Vir Biotechnol San Francisco CA 94158 USA;
Vir Biotechnol San Francisco CA 94158 USA;
机译:在末期肾脏疾病中SARS-COV-2感染后中和抗体应答和防止革新
机译:鼠单克隆抗体对受体结合结构域的SARS-COV-2中和正宗野生型SARS-COV-2以及B.1.1.7和B.1.351病毒,保护<斜体切换=“是”>在体内< /斜体>在鼠标模型中以中和依赖性方式
机译:病例报告:在高水平疫苗诱导的中和抗体反应存在下,用SARS-COV-2感染
机译:双特异性多价HIV-1中和抗体效果抑制了SHIV感染
机译:调查喀麦隆雅温得在各种HIV-1非洲感染中的中和抗体反应。
机译:用SARS-COV-2的受体结合结构域免疫ELICITS抗体交错中和SARS-COV-2和SARS-COV而不依赖于依赖性增强
机译:用SARS-COV-2的受体结合结构域免疫,ELICITS抗体交错中和SARS-COV-2和SARS-COV而不依赖于依赖性增强